Pyrotinib is an oral small-molecule tyrosine kinase inhibitor (TKI) primarily indicated for the treatment of HER2-positive breast cancer. It irreversibly inhibits the HER2 receptor, thereby blocking tumor cell growth signal transduction and delaying disease progression. Currently approved in China for second-line treatment of HER2-positive metastatic breast cancer in combination with capecitabine, clinical studies have demonstrated that it significantly prolongs patients' progression-free survival, though attention should be paid to common adverse reactions such as diarrhea.
I. Mechanism of Action and Indications
1. Targeting the HER2 Signaling Pathway
Pyrotinib exerts its effect by selectively inhibiting the tyrosine kinase activity of HER1 (EGFR), HER2, and HER4 receptors, blocking key signal transduction pathways that regulate tumor cell proliferation, differentiation, and survival. Unlike macromolecular agents such as trastuzumab, its small-molecule structure enables it to cross the blood-brain barrier, potentially yielding therapeutic benefits for patients with brain metastases.
2. Approved Indications
Approved by the National Medical Products Administration (NMPA) of China, Pyrotinib is indicated for patients with HER2-positive metastatic breast cancer who have failed prior treatment with trastuzumab and taxanes. The combination regimen with capecitabine has been recommended as a second-line treatment option in multiple clinical guidelines.
II. Clinical Efficacy and Supporting Data
1. Clinical Trial Results
The PHOEBE study demonstrated that the median progression-free survival (mPFS) in the pyrotinib plus capecitabine group reached 12.5 months, which was significantly superior to the 6.8 months observed in the lapatinib plus capecitabine group. The objective response rate (ORR) was 67.2%, confirming its robust ability to delay disease progression.
2. Comparison with Other Agents
Compared with lapatinib, a TKI of the same class, pyrotinib binds irreversibly to the HER2 receptor, resulting in stronger inhibitory efficacy and a lower risk of drug resistance. It serves as a crucial subsequent treatment option for patients who have failed trastuzumab therapy.
III. Adverse Reactions and Management
1. Common Adverse Reactions
Diarrhea: With an incidence rate of approximately 90%, most cases are Grade 1-2 and can be managed with medications such as loperamide.
Hand-Foot Syndrome: Occurring in around 30% of patients, it presents as redness, swelling, and desquamation of the hands and feet, requiring moisturization and reduced friction exposure.
Other Reactions: Nausea, vomiting, leukopenia, etc., most of which can be alleviated with symptomatic treatment.
2. Dose Adjustment
In the event of Grade 3 or higher adverse reactions, treatment should be suspended until symptoms resolve to Grade ≤1, followed by stepwise dose reduction (e.g., from 400 mg/day to 320 mg/day or 240 mg/day).
IV. Precautions for Administration
1. Contraindications
Hypersensitivity to any component of the drug.
Not recommended for patients with severe hepatic impairment (Child-Pugh Class C).
2. Drug Interactions
Concomitant use with potent CYP3A4 inhibitors (e.g., clarithromycin) or inducers (e.g., rifampicin) should be avoided, as these may affect the plasma concentration of pyrotinib.
Co-administration with proton pump inhibitors (PPIs) (e.g., omeprazole) may reduce pyrotinib absorption; an interval of at least 2 hours between administrations is recommended.
3. Special Populations
Pregnancy: Contraindicated due to embryotoxic potential.
Lactation: Breastfeeding should be discontinued during treatment.
Elderly Patients: Close monitoring of hepatic and renal function, as well as adverse reactions, is required.
V. Research Progress and Future Outlook
Ongoing clinical trials are evaluating pyrotinib in HER2-positive gastric cancer and adjuvant treatment of breast cancer. Preliminary data have shown manageable safety profiles and potential efficacy when pyrotinib is combined with chemotherapy for gastric cancer, supporting its potential for indication expansion. Additionally, exploratory studies targeting brain metastases are underway.
